Dr. Reddy’s (NYSE: RDY) tightens rules on unpublished price sensitive information

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited filed a Form 6-K to inform investors that its Board has approved an amended Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information under India’s SEBI insider trading rules.

The code designates the Head of Investor Relations as Chief Investor Relations Officer, responsible for prompt, uniform disclosure of any unpublished price sensitive information to all stock exchanges and on the company website, and for quickly correcting any inadvertent selective disclosure. It restricts use of such information to a strict “need to know” basis, explicitly bars sharing it via social media, and allows sharing only for legitimate purposes with partners and advisors who are then treated as insiders.

The company will maintain a structured digital database of who shares and receives unpublished price sensitive information, including identifiers such as PAN, for at least eight years and longer if required for SEBI proceedings. The Board will review and update the code to align with future changes in SEBI regulations and listing requirements.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

March, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                             Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                               No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated March 24, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: March 24, 2026	By:	/s/ K Randhir Singh
		Name: K Randhir Singh
		Title:  Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

March 24, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: ‘Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information’

Ref: Disclosure under Regulation 8 (2) of SEBI (Prohibition of Insider Trading) Regulations, 2015

In accordance with the provisions of Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 (“PIT Regulations”), please find enclosed herewith a copy of the amended ‘Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive  Information’, as approved by the Board of Directors of the Company at their meeting held today, i.e., March 24, 2026.

A copy of the same is also available at the website of the Company at: Code of fair disclosure

This is for your information and records.

Thanking you,

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Encl: as above

DR. REDDY’S LABORATORIES

LIMITED

Code of Practices and Procedures for Fair Disclosures of

Un-published Price Sensitive Information

Code of Practices and Procedures for Fair Disclosures of Un-published Price

Sensitive Information

A) The Code

Dr. Reddy’s Laboratories Limited (below referred to as “the Company”) has adopted this Code in compliance with the ‘Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015’, (“SEBI PIT Regulation”) as amended from time to time.

B) Definitions for the purpose of the Code

“Un-published Price Sensitive Information” (“UPSI”) shall mean an UPSI as defined under clause (n) of regulation 2 (1) of the SEBI PIT Regulation, as amended time to time.

“Chief Investor Relations Officer” for the purpose of this Code - Head of Investor Relations shall be designated as Chief Investor Relations Officer.

C) Uniform and universal disclosure of UPSI

The Company shall promptly furnish to the Stock Exchanges where the securities of the Company are listed, the material information related to any UPSI as soon as credible and concrete information comes into being. The information may also be hosted on the Company’s website.

The Chief Investor Relations Officer shall ensure that dissemination of the UPSI is uniform and universal to avoid selective disclosures. In case any UPSI gets disclosed selectively, inadvertently or otherwise, the Chief Investor Relations officer shall ensure that such information is made generally available promptly, but not later than the time specified in any laws/ regulations applicable to the Company. In this context, rumours or media speculation shall not be considered as selective disclosure.

D) Response to Regulatory Authorities

The Company shall provide appropriate and fair responses to regulatory authorities, in related to queries on, news reports and requests for verification of market rumours, in accordance with the Company’s “Policy on Determination of Materiality” and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

E) Interactions with Analysts, Investors and Research Personnel

The Company in order to have better investor relations, may interact with investors, investing community, equity research analysts and other members of the investing community from time to time. However, during these interactions the Company shall ensure that no UPSI is disclosed selectively to any one or group of research analysts or investors, to the disadvantage of other stakeholders.

To ensure official documentation of disclosures, the transcripts or recordings of the proceedings of any investor conference organised by the Company, may be made available on the Company’s website, as required under the law applicable to the Company, along with the documents / presentation, if any, made at such conference.

F) Handling of all UPSI

The Company shall ensure that UPSI is handled on a "need to know" basis, i.e., UPSI should only be disclosed to those within the Company or other persons who need the information for legitimate purposes, performance of his / her duties or discharge of his / her legal obligations in ordinary course of business.

2

Further, the disclosure of UPSI or any material non-public information through any social media platform is strictly prohibited.

In the event the Company becomes aware that it, or any person acting on its behalf, has inadvertently disclosed UPSI or any material non-public information, the Company shall ensure that such information/intimation is publicly disseminated promptly, and not later than 24 hours of identifying the unintentional disclosure.

G) Determination of Legitimate Purpose

UPSI shall only be shared with other person (s) or entity (ies) only for furtherance of legitimate purpose, performance of duties or discharge of legal obligation.

The term “legitimate purpose” shall include sharing of unpublished price sensitive information in the ordinary course of business by an insider with partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals or other advisors or consultants, provided that such sharing has not been carried out to evade or circumvent the prohibitions of SEBI PIT Regulation.

Any persons or entities (as mentioned above) with whom UPSI is shared for Legitimate Purpose, shall be construed as an insider and due notice will be given to them at the time of sharing such information to maintain confidentiality in compliance with the provisions of SEBI PIT Regulation.

Such notice shall outline the duties, responsibilities and liabilities related to misuse or unwarranted use of such information and shall seek information including ‘Permanent Account Number’ (“PAN”) or any other identifier authorised by law where PAN is not available.

Such person (s) or entity (ies) shall have no objection, in case the Company shares with any regulatory authority, their details e.g. PAN or any other legal identifier (in case PAN not available), etc.

H) Maintenance of Structured Digital Database

The Chief Executive Officer, under supervision of Board of Directors, shall maintain a digital database containing the nature of the UPSI, the names of the persons who have shared such information, and the names and PAN (or any other valid identifier, where PAN is not available) of the persons with whom the information has been shared.

The structured digital database shall be preserved for a period of not less than eight years from the completion of the relevant transaction. If any information is sought by SEBI in connection with an investigation or enforcement proceedings, the relevant records shall be retained until the conclusion of such proceedings.

I) Review of Code

This Code shall be reviewed by the Board and may be amended from time to time in line with any amendments made to the SEBI PIT Regulation, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and such other guidelines or regulations issued by SEBI. In the events of inconsistency of this Code with SEBI Act, SEBI PIT Regulation, or any rules, regulations or circular prescribed thereunder, the relevant provisions of the applicable law shall override this Code.

last modified on March 24, 2026

3

FAQ

What did Dr. Reddy’s Laboratories (RDY) disclose in this Form 6-K?

Dr. Reddy’s disclosed Board approval of an amended Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information, aligning its practices with SEBI’s Prohibition of Insider Trading Regulations, 2015, and related Indian listing rules on disclosure and handling of sensitive information.

What is the purpose of Dr. Reddy’s amended code on unpublished price sensitive information?

The code sets procedures for fair, uniform disclosure of unpublished price sensitive information and restricts its use to a strict need-to-know basis. It aims to prevent selective disclosure, govern interactions with regulators and investors, and ensure compliance with SEBI insider trading and listing regulations.

Who is responsible for managing UPSI disclosures at Dr. Reddy’s Laboratories?

The Head of Investor Relations is designated as the Chief Investor Relations Officer under the code. This officer must ensure prompt, uniform dissemination of any unpublished price sensitive information to all stock exchanges, update the company website, and correct any inadvertent selective disclosures in line with applicable laws.

How does Dr. Reddy’s handle sharing UPSI for legitimate purposes?

Unpublished price sensitive information may be shared only for legitimate purposes, in the ordinary course of business, with parties such as partners, lenders, advisors, auditors, and consultants. These recipients are treated as insiders and receive formal notice outlining confidentiality duties, liabilities, and required identifiers like PAN.

What record-keeping requirements are included in Dr. Reddy’s UPSI code?

The Chief Executive Officer, under Board supervision, must maintain a structured digital database detailing the nature of unpublished price sensitive information, who shared it, and recipients’ names and identifiers. These records are kept for at least eight years and longer if SEBI requests them for proceedings.

Does Dr. Reddy’s allow disclosure of UPSI on social media platforms?

The code strictly prohibits disclosure of unpublished price sensitive information or any material non-public information through social media platforms. If the company becomes aware of any inadvertent disclosure, it must publicly disseminate the information promptly, and no later than twenty-four hours after identifying the unintentional disclosure.

How will Dr. Reddy’s keep its UPSI disclosure code up to date?

The Board of Directors will periodically review the code and may amend it to reflect changes in SEBI’s Prohibition of Insider Trading Regulations, SEBI listing obligations, or other SEBI guidelines. Where inconsistencies arise, applicable SEBI laws and regulations override the provisions of the company’s code.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 75.4 KB